RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers

RenovoRx’s Phase III TIGeR-PaC trial is fully enrolled and had recorded 78 of 86 required events; final events are expected in the first half of 2027, with top-line results anticipated in the second half of 2027. An interim analysis indicated a 65% reduction in toxicities versus systemic chemotherapy, but the survival trend was not statistically significant. RenovoCath adoption expanded to 21 treatment centers , up from roughly four or five last year, as physicians cited its potential to deliver localized chemotherapy with lower systemic toxicity and provide a maintenance or “chemotherapy holiday” option for locally advanced pancreatic cancer. RenovoRx reported $1.5 million in first-half revenue and approximately $900,000 in quarterly revenue, and management is targeting potential break-even in the fourth quarter of next year. Hospital approval cycles typically take four to six months. RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading. Shaun Bagai, RenovoRx’s chief executive officer, said the company’s approach is designed to deliver chemotherapy locally to tumors while reducing the systemic toxicity associated with intravenous chemotherapy. The TAMP procedure uses the FDA-cleared RenovoCath device, which is positioned through an artery near the tumor. Two balloons isolate blood flow in a targeted area, allowing clinicians to administer therapy under pressure into nearby tissue, according to Bagai. Bagai said pancreatic tumors can be difficult to treat because they often have limited blood supply and fibrotic tissue that can impede drug penetration. RenovoRx’s approach is intended to increase local drug concentration while limiting exposure elsewhere in the body. Physicians cite need for lower-toxicity options Dr. Dae Won Kim, a gastrointestinal medical oncologist at Moffitt Cancer Center, said treatment depends on whether pancreatic cancer is resectable. Patients with resectable disease may undergo surgery followed by chemotherapy, while those with locally advanced or metastatic disease generally receive chemotherapy, with radiation also used for localized disease. Kim said roughly 50% to 55% of patients have metastatic disease at diagnosis, 30% to 35% have locally advanced unresectable disease, and only 10% to 15% can proceed directly to surgery. For unresectable cases, patients often require extended chemotherapy treatment, but cumulative side effects can limit their ability to remain on therapy, Kim said. He identified lower toxicity as a central unmet need, particularly for patients who have already received months of chemotherapy and radiation. Kim, who disclosed research support from Revolution Medicines and RenovoCath, said TAMP may offer a maintenance option for locally advanced patients after initial chemotherapy and radiation. He said patients he has treated with TAMP generally tolerated planned treatment courses and, in one case, regained enough strength to resume systemic chemotherapy after later developing liver metastases. Kim also discussed emerging KRAS-targeted therapies, including daraxonrasib, saying such drugs could affect pancreatic cancer treatment but would not eliminate the need for local therapies. He said the agent may have toxicity limitations, including severe skin rash in a large proportion of patients, and may require treatment interruptions or dose reductions for some individuals.